Science · 2025 · 28 citations · 41 references
MedicineOncologyPharmacologyCell SignalingMolecular OncologySignal TransductionCancer Cell SignalingOncogenic Signaling PathwaysPharmacodynamics Of Anticancer AgentsRas Family OncogenesSarcoma PharmacotherapyTyrosine Kinase InhibitorsCyclin-dependent Kinase InhibitorsInsulin SignalingKras G12c InhibitionOncogenic Ras MutationsPi3k InhibitorsPi3k SignalingPik3ca MutationsTherapeutic Growth Inhibition
BBO-10203 is an orally available drug that covalently and specifically binds to the rat sarcoma (RAS)–binding domain of phosphoinositide 3-kinase α (PI3Kα), preventing its activation by HRAS, NRAS, and KRAS. It inhibited PI3Kα activation in tumors with oncogenic mutations in KRAS or PIK3CA and in tumors with human epidermal growth factor receptor 2 (HER2) amplification or overexpression. In preclinical models, BBO-10203 caused significant tumor growth inhibition across multiple tumor types and showed enhanced efficacy in combination with inhibitors of cyclin-dependent kinase 4/6 (CDK4/6), estrogen receptor (ER), HER2, and KRAS-G12C mutant, including in tumors harboring mutations in Kelch-like ECH-associated protein 1 (KEAP1) and serine/threonine kinase 11 (STK11). Notably, these antitumor effects occurred without inducing hyperglycemia, because insulin signaling does not depend on RAS-mediated PI3Kα activation to promote glucose uptake.
41
Features and development of <i>Coot</i>
Paul Emsley, Bernhard Lohkamp, W. G. Scott et al. · Acta Crystallographica Section D Biological Crystallography · 2010 · 29.6K citations · Full text
Wolfgang Kabsch · Acta Crystallographica Section D Biological Crystallography · 2010 · 16.9K citations · Full text
Dorothée Liebschner, Pavel V. Afonine, Matthew L. Baker et al. · Acta Crystallographica Section D Structural Biology · 2019 · 7.4K citations · Full text